The future of plague vaccines: Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate

Jason A. Rosenzweig, Ashok Chopra

Research output: Contribution to journalArticle

7 Scopus citations


Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.

Original languageEnglish (US)
Pages (from-to)659-661
Number of pages3
JournalExpert Review of Vaccines
Issue number6
StatePublished - Jun 2012



  • balanced lethal plasmids
  • F1
  • LcrV antigen
  • Salmonella typhimurium-attenuated ΔphoP/Q mutant
  • Yersinia pestis vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this